A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Psoriasis

In brief

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.

Key facts

Study ID
NCT04152382
Run by
Eli Lilly and Company
People needed
30
Starts
2019-11-20
Expected to finish
2022-02-09
Last updated by the study team
2022-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.